Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk

Clinical Oncology

Volumn 29, Issue 4, 2017, Pages 263-273

  Dean, J A ^a   Welsh, L C ^a   Wong, K H ^a   Aleksic, A ^a   Dunne, E ^a   Islam, M R ^a   Patel, A ^a   Patel, P ^a   Petkar, I ^a   Phillips, I ^a   Sham, J ^a   Schick, U ^a   Newbold, K L ^a,b   Bhide, S A ^a,b   Harrington, K J ^a,b   Nutting, C M ^a,b   Gulliford, S L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Head and neck radiotherapy; machine learning; mucositis; NTCP modelling; OAR delineation; oral mucosa

Indexed keywords

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MOUTH MUCOSA; NORMAL TISSUE COMPLICATION PROBABILITY MODEL; ORAL MUCOSAL SURFACE ORGAN AT RISK; ORAL MUCOSITIS; ORGANS AT RISK; PRIORITY JOURNAL; PROBABILITY; RADIATION INJURY; RADIOTHERAPY DOSAGE; RANDOM FOREST; ADVERSE EFFECTS; BIOLOGICAL MODEL; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MUCOSITIS; PROCEDURES; RADIATION RESPONSE; REPRODUCIBILITY; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; HEAD AND NECK NEOPLASMS; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MODELS, BIOLOGICAL; MOUTH MUCOSA; MUCOSITIS; PROBABILITY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 85008689607     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.12.001     Document Type: Article

References (52)

1. [1] Sanguineti, G., Gunn, G.B., Parker, B.C., Endres, E.J., Zeng, J., Fiorino, C., Weekly dose-volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 79 (2011), 52–59, 10.1016/j.ijrobp.2009.10.057.
2. [2] Trotti, A., Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47 (2000), 1–12, 10.1016/S0360-3016(99)00558-1.
3. [3] Kelly, C., Paleri, V., Downs, C., Shah, R., Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg 136 (2007), 108–111, 10.1016/j.otohns.2006.06.1278.
4. [4] Trotti, A., Bellm, L.A., Epstein, J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66 (2003), 253–262, 10.1016/S0167-8140(02)00404-8.
5. [5] Bourhis, J., Overgaard, J., Audry, H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006), 843–854, 10.1016/S0140-6736(06)69121-6.
6. [6] Jackson, S.M., Weir, L.M., Hay, J.H., Tsang, V.H., Durham, J.S., A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol 43 (1997), 39–46, 10.1016/S0167-8140(97)01944-0.
7. [7] Maciejewski, B., Skladowski, K., Pilecki, B., et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. Radiother Oncol 40 (1996), 137–145, 10.1016/0167-8140(96)01776-8.
8. [8] Sonis, S.T., Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45 (2009), 1015–1020, 10.1016/j.oraloncology.2009.08.006.
9. [9] Bentzen, S.M., Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6 (2006), 702–713, 10.1038/nrc1950.
10. [10] Denham, J.W., Peters, L.J., Johansen, J., et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?. Radiother Oncol 52 (1999), 157–164, 10.1016/S0167-8140(99)00107-3.
11. [11] Lambin, P., van Stiphout, R.G.P.M., Starmans, M.H.W., et al. Predicting outcomes in radiation oncology – multifactorial decision support systems. Nat Rev Clin Oncol 10 (2013), 27–40, 10.1038/nrclinonc.2012.196.
12. [12] Sanguineti, G., Endres, E.J., Gunn, B.G., Parker, B., Is there a “mucosa-sparing” benefit of IMRT for head-and-neck cancer?. Int J Radiat Oncol Biol Phys 66 (2006), 931–938, 10.1016/j.ijrobp.2006.05.060.
13. [13] Dean, J.A., Wong, K.H., Welsh, L.C., et al. Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy. Radiother Oncol 120 (2016), 21–27, 10.1016/j.radonc.2016.05.015.
14. [14] Bhide, S.A., Gulliford, S., Fowler, J., et al. Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. Radiother Oncol 97 (2010), 86–91, 10.1016/j.radonc.2010.08.013.
15. [15] Dean, J.A., Welsh, L.C., Gulliford, S.L., Harrington, K.J., Nutting, C.M., A novel method for delineation of oral mucosa for radiotherapy dose-response studies. Radiother Oncol 115 (2015), 63–66, 10.1016/j.radonc.2015.02.020.
16. [16] Dean, J.A., Welsh, L.C., McQuaid, D., et al. Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk. Radiother Oncol 119 (2016), 166–171, 10.1016/j.radonc.2016.02.022.
17. [17] Nutting, C.M., Morden, J.P., Harrington, K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12 (2011), 127–136, 10.1016/S1470-2045(10)70290-4.
18. [18] Miah, A.B., Bhide, S.A., Guerrero-Urbano, M.T., et al. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 82 (2012), 539–547, 10.1016/j.ijrobp.2010.09.055.
19. [19] Miah, A.B., Schick, U., Bhide, S.A., Clark, C.H., Bidmead, A.M., Bodla, S., A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: the application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes. Br J Cancer, 2014, 1–7, 10.1038/bjc.2014.553.
20. [20] Miah, A.B., Bhide, S.A., Del Rosario, L., et al. Induction chemotherapy followed by chemo-intensity-modulated radiotherapy for locally advanced nasopharyngeal cancer. Clin Oncol 28 (2016), e1–e7, 10.1016/j.clon.2016.01.012.
21. [21] Gujral, D.M., Miah, A.B., Bodla, S., et al. Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. Oral Oncol 50 (2014), 1089–1097, 10.1016/j.oraloncology.2014.07.018.
22. [22] Richards, T.M., Bhide, S.A., Miah, A.B., et al. Total mucosal irradiation with intensity-modulated radiotherapy in patients with head and neck carcinoma of unknown primary: a pooled analysis of two prospective studies. Clin Oncol 28 (2016), e77–e84, 10.1016/j.clon.2016.04.035.
23. [23] Nutting, C., Morden, J.P., Beasley, M., et al. First results of COSTAR: a randomised trial of 3-dimensional conformal radiotherapy (3DCRT) vs cochlea-sparing intensity modulated radiotherapy (CS-IMRT) in patients with parotid cancer. J Clin Oncol, 34 (suppl), 2016, 6006.
24. [24] The National Cancer Institute, Common Toxicity Criteria (CTC) Version 2.0. 1999.
25. [25] The National Cancer Institute, Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006.
26. [26] Tucker, S.L., Michalski, J.M., Bosch, W.R., et al. Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06. Radiother Oncol 104 (2012), 109–113, 10.1016/j.radonc.2012.04.023.
27. [27] Narayan, S., Lehmann, J., Coleman, M.A., et al. Prospective evaluation to establish a dose response for clinical oral mucositis in patients undergoing head-and-neck conformal radiotherapy. Int J Radiat Oncol Biol Phys 72 (2008), 756–762, 10.1016/j.ijrobp.2008.01.060.
28. [28] Sonis, S.T., The pathobiology of mucositis. Nat Rev Cancer 4 (2004), 277–284, 10.1038/nrc1318.
29. [29] Buettner, F., Miah, A.B., Gulliford, S.L., et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol 103 (2012), 82–87, 10.1016/j.radonc.2012.02.006.
30. [30] Hoerl, A.E., Kennard, R.W., Ridge regression: biased estimation for nonorthogonal problems. Technometrics 12 (1970), 55–67, 10.1080/00401706.1970.10488634.
31. [31] Tibshirani, R., Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B 58 (1996), 267–288, 10.1111/j.1467-9868.2011.00771.x.
32. [32] Breiman, L., Random forests. Mach Learn 45 (2001), 5–32, 10.1023/A:1010933404324.
33. [33] Moons, K.G.M., Altman, D.G., Reitsma, J.B., et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 162 (2015), W1–W73, 10.7326/M14-0698.
34. [34] Moons, K.G.M., de Groot, J.A.H., Bouwmeester, W., et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med, 11, 2014, 10.1371/journal.pmed.1001744.
35. [35] Brier, G.W., Verification of forecasts expressed in terms of probaility. Mon Weather Rev 78 (1950), 1–3, 10.1126/science.27.693.594.
36. [36] Good, I.J., Rational decisions. J R Stat Soc Ser B 14 (1952), 107–114.
37. [37] Steyerberg, E.W., Vickers, A.J., Cook, N.R., et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21 (2010), 128–138, 10.1097/EDE.0b013e3181c30fb2.
38. [38] Pavlou, M., Ambler, G., Seaman, S.R., et al. How to develop a more accurate risk prediction model when there are few events. Br Med J, 351, 2015, h3868, 10.1136/bmj.h3868.
39. [39] Rossum, G., Python Reference Manual. 1995.
40. [40] McKinney, W., Data structures for statistical computing in Python. Proc 9th Python Sci Conf, 2010, 51–56.
41. [41] Pedregosa, F., Varoquaux, G., Gramfort, A., et al. Scikit-learn: machine learning in Python. J Mach Learn Res 12 (2011), 2825–2830.
42. [42] Strobl, C., Boulesteix, A.-L., Zeileis, A., Hothorn, T., Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics, 8, 2007, 25, 10.1186/1471-2105-8-25.
43. [43] Sonis, S.T., Eilers, J.P., Epstein, J.B., et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Cancer 85 (1999), 2103–2113, 10.1002/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2–0.
44. [44] Otter, S., Schick, U., Gulliford, S., et al. Evaluation of the risk of grade 3 oral and pharyngeal dysphagia using atlas-based method and multivariate analyses of individual patient dose distributions. Int J Radiat Oncol Biol Phys 93 (2015), 507–515, 10.1016/j.ijrobp.2015.07.2263.
45. [45] Sanguineti, G., Sormani, M.P., Marur, S., et al. Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 83 (2012), 235–242, 10.1016/j.ijrobp.2011.06.2000.
46. [46] Wang, Z.-H., Zhang, S.-Z., Zhang, Z.-Y., et al. Protecting the oral mucosa in patients with oral tongue squamous cell carcinoma treated postoperatively with intensity-modulated radiotherapy: a randomized study. Laryngoscope 122 (2012), 291–298, 10.1002/lary.22434.
47. [47] Vera-Llonch, M., Oster, G., Hagiwara, M., Sonis, S., Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106 (2006), 329–336, 10.1002/cncr.21622.
48. [48] Elting, L.S., Keefe, D.M., Sonis, S.T., et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113 (2008), 2704–2713, 10.1002/cncr.23898.
49. [49] Epstein, J.B., Beaumont, J.L., Gwede, C.K., et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 109 (2007), 1914–1922, 10.1002/cncr.22620.
50. [50] Werbrouck, J., De Ruyck, K., Duprez, F., et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 73 (2009), 1187–1195, 10.1016/j.ijrobp.2008.08.073.
51. [51] Sonis, S., Antin, J., Tedaldi, M., Alterovitz, G., SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 19 (2013), 721–772, 10.1111/odi.12146.
52. [52] Jaffray, D.A., Lindsay, P.E., Brock, K.K., Deasy, J.O., Tome, W.A., Accurate accumulation of dose for improved understanding of radiation effects in normal tissue. Int J Radiat Oncol Biol Phys 76 (2010), 135–139, 10.1016/j.ijrobp.2009.06.093.